Stefano Del Prato, MD PhD

Stefano Del Prato, MD PhD

Professor of Endocrinology and Metabolism
School of Medicine, University of Pisa
Chief of the Section of Diabetes
University of Pisa, Italy
Clinical Associate Professor of Medicine
University of Texas, San Antonio Health Science Center
San Antonio, Texas, USA

Related Videos

Do you see safety signals associated with ultra-aggressive LDL-C lowering and what is the role of PAD as a risk factor guiding LDL-C reduction? Video

Do you see safety signals associated with ultra-aggressive LDL-C lowering and what is the role of PAD as a risk factor guiding LDL-C reduction?

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population? Video

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL? Video

Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL?

Given that ODYSSEY Outcomes has shown not only reduction in CV events, but also a reduction in associated, all-cause mortality, what is the role of PCSK9 inhibitors in diabetes patients with a prior ACS event? Video

Given that ODYSSEY Outcomes has shown not only reduction in CV events, but also a reduction in associated, all-cause mortality, what is the role of PCSK9 inhibitors in diabetes patients with a prior ACS event?

In the Type 2 diabetes population that you manage in your, what percentage of patients do you estimate do not achieve risk-appropriate LDL-C for any number of reasons? Is it as high as 10%, as reported in by some diabetes experts? Video

In the Type 2 diabetes population that you manage in your, what percentage of patients do you estimate do not achieve risk-appropriate LDL-C for any number of reasons? Is it as high as 10%, as reported in by some diabetes experts?